Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Transcript
What is the importance of patient-reported outcomes in cardiology and how can they be better incorporated into payment models?
I think, I’m a little bit biased because a do a little research in this area, but I think patient-reported outcomes are critically important certainly to cardiologists and medicine at large. Patient-reported outcomes focus on what is important to patients, outcomes that matter to patients, what is the patient’s quality of life, how are they feeling, how functional are patients, how much time can they spend with their families. These are things that are critically important above and beyond traditional outcomes such as mortality and readmissions.
We have some very good ones in cardiology. We have PROMs, patient-reported outcome measures, that have been developed by John Spertus, MD, MPH, who is really one of the fathers of patient-reported outcome measures from Kansas City. John developed the Kansas City Cardiomyopathy Questionnaire and the Seattle Angina Questionnaire. These are questionnaires that are highly predictive of mortality and readmissions and also measure quality of life. These are measures that very easily integrated into any kind of value-measured program.
Other PROMs are being developed to focus on conditions such as atrial fibrillation and you start combining those with more general measures of quality of life and NIH [National Institutes of Health] is are developing some of these. They’re called the PROMIS measures. You really have the underpinnings of a very robust measuring system.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More